Drugs / Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Follow last change Apr 2021 re-read 3 minutes ago

Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)

also known as HPV vaccine

Developed for: anogenital human papillomavirus infection · cervical cancer
Investigated by: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. · Xiamen Innovax Biotech Co., Ltd · Xiamen University

today NCT03935204 · Ph 2

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT03935204	May → Oct 2019	anogenital human papillomavirus infection, cervical cancer	Xiamen University	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)	“This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58...” NCT03935204 ↗
Known as	HPV vaccine	“This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58...” NCT03935204 ↗
Modality	Vaccine	“Recombinant Human Papillomavirus Vaccine” NCT03935204 ↗
Route	Intramuscular	“HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.” NCT03935204 ↗